Search
Furazolidone
go.drugbank.com/drugs/DB00614InvestigationalVet approvedA nitrofuran derivative with antiprotozoal and antibacterial activity. Furazolidone binds bacterial DNA which leads to the gradual inhibition of monoamine oxidase.
Categories: metronidazole and furazolidone, Genito Urinary System and Sex HormonesSynonyms: N-(5-Nitro-2-furfurylidene)-3-amino-2-oxazolidone, 5-Nitro-N-(2-oxo-3-oxazolidinyl)-2-furanmethanimineOcrelizumab
go.drugbank.com/drugs/DB11988ApprovedInvestigationalIt was later approved by Health Canada in August 2017, making the drug the first available treatment for PPMS in both the US and Canada. … [L1199] In phase 3 clinical trials of patients with PPMS, treatment with ocrelizumab led to lower clinical and MRI progression rates compared to placebo.
Categories: Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating AgentsProducts: OCREVUS 300mg/10mL Concentrate for Solution for Infusion, OCREVUS® CONCENTRADO PARA SOLUCION PARA INFUSION 300MG/10MLSaxagliptin
go.drugbank.com/drugs/DB06335ApprovedInvestigationalSaxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.
Mixtures: Saxagliptin and Metformin, Saxagliptin and MetforminCategories: Alimentary Tract and Metabolism, metformin and saxagliptinEsketamine
go.drugbank.com/drugs/DB11823ApprovedInvestigational[L5596,A175462] On March 5, 2019, the nasal spray drug, _esketamine_, also known as _Spravato_ (by Janssen Pharmaceuticals), was approved by the FDA for treatment-resistant major depression. … and therapies.
Categories: Non-Competitive N-Methyl D-Aspartate (NMDA) Receptor AntagonistsSynonyms: (S)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanoneRavulizumab
go.drugbank.com/drugs/DB11580ApprovedInvestigational[A244465] Ravulizumab was first approved by the FDA on December 21, 2018, for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome in children and adults. … [A244460] It works by blocking terminal complement-mediated inflammation, cell activation, and cell lysis in blood disorders associated with the destruction of red blood cells, thrombosis, and impaired
Categories: Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating AgentsProducts: ULTOMIRIS ® RAVULIZUMAB 100MG/ML., Ultomiris 100mg/mL Concentrate For Solution For InfusionSarilumab
go.drugbank.com/drugs/DB11767ApprovedInvestigational[A27262] Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid … [A27265] RA is a chronic inflammatory disease characterized by polyarthritis, and its treatment has been challenged by the different responses in every patient.
Categories: Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating AgentsProducts: KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG, KEVZARA Solution for Injection in Pre-filled Pen 150mgPolatuzumab vedotin
go.drugbank.com/drugs/DB12240ApprovedInvestigational[L6658] Polatuzumab vedotin was granted accelerated FDA approval on June 10, 2019 [A254936] and was approved by Health Canada on July 9, 2020.[L44141] … Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells.
Categories: Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating AgentsProducts: POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 140MG, POLIVY 140mg Powder For Concentrate For Solution For InfusionPodophyllin
go.drugbank.com/drugs/DB09094ApprovedPodophyllin is a resin extracted from the roots of _Podophyllum peltatum_ (American mandrake) and _Podophyllum emodi_, which contains numerous compounds, amongst which is podophyllin (as well as the drug
Mixtures: PODOPHYLLIN PAINT, CO.Categories: Skin and Mucous Membrane AgentsUrsodeoxycholic acid
go.drugbank.com/drugs/DB01586ApprovedInvestigational[A256272] UDCA was first approved by the FDA in 1987 for dissolution of gallstones and for primary biliary cirrhosis in 1996. … [A256267,A256463] UDCA was first characterized in the bile of the Chinese black bear and is formed by 7b-epimerization of [chenodeoxycholic acid], which is a primary bile acid.
Categories: Bile Acids and Salts, Bile and Liver TherapyProducts: URSOFALK 250MG, URSO 1A PHARMA 250MGTrastuzumab
go.drugbank.com/drugs/DB00072ApprovedInvestigationalKanjinti (trastuzumab-anns)[L14135] and Hercessi[L52840] are other biosimilars approved by the FDA. In Canada, biosimilars ONTRUZANT[[L40303, L40308] and Adheroza[L52835] are approved. … Trastuzumab binds to HER2 and suppresses cancer cell growth, proliferation, and survival directly and indirectly [A121].
Categories: Amino Acids, Peptides, and Proteins, pertuzumab and trastuzumabProducts: LICAR® POLVO LIOFILIZADO 150MG, LLICAR® POLVO LIOFILIZADO 150MG